|
Getting your Trinity Audio player ready...
|
Rapid Dose Therapeutics (CSE: DOSE; OTCQB: RDTCF), a biotechnology and drug delivery innovation company, is accelerating clinical validation of its proprietary QuickStrip™ oral thin film delivery system through expanded cannabinoid research and a high-profile study supported by the National Football League (NFL).
Independent research led by university investigators is examining the role of naturally produced cannabinoids in pain management, concussion recovery, and neuroprotection in contact sports, highlighting growing institutional interest in cannabinoid therapeutics and sports medicine innovation.
Stocks to Watch Under $1: Ensysce Biosciences (NASDAQ: ENSC), OneMedNet Inc (NASDAQ: ONMD), Veea Inc (NASDAQ: VEEA), TMD Energy Ltd (NYSE: TMDE) and Kartoon Studios (NYSE: TOON) trading actively in early trading now!
In parallel, a clinical study is evaluating the bioavailability of CBD delivered via QuickStrip™ compared to traditional oral formats. The research measures pharmacokinetic data, including CBD plasma concentration and absorption efficiency, to determine whether oral thin film delivery enhances systemic uptake. More than 60% of participant data has been extracted, with enrollment continuing through Q2 2026, alongside real-time and accelerated stability testing.
If clinical data confirm improved absorption and rapid onset, QuickStrip™ could significantly strengthen its positioning within the oral thin film drug delivery market, the CBD clinical research sector, and the broader pharmaceutical and nutraceutical industries. Watch QuickStrip™ Drug Delivery System Video Now!
Management believes QuickStrip™ represents a next-generation patient delivery system designed to disrupt traditional capsules, oils, and tablets by offering rapid, discreet, and controlled dosing. With applications spanning pharmaceutical drug delivery, wellness products, nicotine alternatives, and cannabinoid therapeutics, the platform is being positioned as a scalable solution capable of reshaping how active ingredients are administered in both medical and consumer markets.
For investors searching “CSE biotech stocks,” “OTCQB life sciences companies,” “oral thin film delivery technology,” and “CBD clinical trial stocks,” Rapid Dose Therapeutics continues to build a data-driven case for platform validation and long-term growth.